VIEW FROM HERE: Sovaldi Redux—The States Muddle Through
By Christopher F. Koller
President of the Milbank Memorial Fund
What kind of coverage decisions are states making about Sovaldi, the new Hepatitis C drug that costs $1,000 a pill or up to $168,000 a treatment? The drug presents new hope for patients, but grave risks to Medicaid and state corrections budgets, both of which must pay for care for a disproportionate number of people with Hepatitis C.
NEW IMPACT FACTOR SCORE
The 2013 Institute for Scientific Information (ISI) Impact Factors were recently readjusted—and The Milbank Quarterly now has an impact factor of 5.391. The ISI impact factor is the gold standard...
TRANFORMING PRIMARY CARE REPORT
A new Milbank Memorial Fund report, “Aligning Payers and Practices to Transform Primary Care: A Report from the Multi-State Collaborative,” describes the efforts in states to take on the challenges of primary care transformation and payment reform.